FY2027 Earnings Estimate for Alumis Issued By HC Wainwright

Key Points

• HC Wainwright projects FY2027 EPS of ($3.37) for Alumis, maintaining a "Buy" rating but trimming its price target to $25 versus a consensus full‑year estimate of ($8.51).
• Most analysts are bullish—one "Strong Buy" and ten "Buy" ratings yield a consensus price target of $38.60 (with Oppenheimer at $55 and Morgan Stanley at $38), citing strong Phase‑3 data for Envu and a planned 2026 FDA submission as catalysts.
• Operationally Alumis missed Q1 revenue and EPS and shows deeply negative margins and ROE, yet insiders and institutions have been buying heavily (director purchased ~588,235 shares for ~$10M and insiders now own 40.7%), signaling insider confidence despite the fundamentals.

Alumis Inc. (NASDAQ:ALMS - Free Report) - HC Wainwright issued their FY2027 earnings per share estimates for shares of Alumis in a research note issued to investors on Monday, March 30th. HC Wainwright analyst M. Kapoor expects that the company will earn ($3.37) per share for the year. HC Wainwright has a "Buy" rating and a $25.00 price target on the stock. The consensus estimate for Alumis' current full-year earnings is ($8.51) per share.

Several other equities analysts also recently issued reports on the stock. Raymond James Financial started coverage on shares of Alumis in a report on Tuesday, March 10th. They set a "strong-buy" rating and a $46.00 price objective on the stock. Stifel Nicolaus began coverage on shares of Alumis in a research report on Wednesday, February 25th. They set a "buy" rating and a $44.00 price target for the company. Guggenheim raised their price target on shares of Alumis from $18.00 to $32.00 and gave the company a "buy" rating in a research note on Wednesday, January 7th. Wells Fargo & Company lifted their price objective on Alumis from $17.00 to $39.00 and gave the stock an "overweight" rating in a report on Tuesday, January 6th. Finally, Leerink Partners increased their target price on Alumis from $20.00 to $32.00 and gave the company an "outperform" rating in a report on Tuesday, January 6th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $38.60.

Alumis Stock Performance

Shares of NASDAQ ALMS opened at $20.21 on Tuesday. The firm has a fifty day moving average of $26.50 and a 200 day moving average of $14.67. The firm has a market cap of $2.57 billion, a PE ratio of -6.60 and a beta of -2.16. Alumis has a one year low of $2.76 and a one year high of $30.60.

Alumis (NASDAQ:ALMS - Get Free Report) last announced its earnings results on Thursday, March 19th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.90) by ($0.05). Alumis had a negative net margin of 1,011.75% and a negative return on equity of 116.97%. The business had revenue of $1.93 million for the quarter, compared to analysts' expectations of $2.75 million.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ALMS. Russell Investments Group Ltd. grew its position in shares of Alumis by 320.9% in the third quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company's stock valued at $26,000 after purchasing an additional 4,894 shares in the last quarter. Police & Firemen s Retirement System of New Jersey lifted its position in Alumis by 199.7% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 10,753 shares of the company's stock worth $32,000 after buying an additional 7,165 shares in the last quarter. New York State Common Retirement Fund boosted its stake in Alumis by 173.7% during the second quarter. New York State Common Retirement Fund now owns 11,767 shares of the company's stock worth $35,000 after buying an additional 7,467 shares during the last quarter. CWM LLC boosted its stake in Alumis by 1,028.7% during the third quarter. CWM LLC now owns 10,384 shares of the company's stock worth $41,000 after buying an additional 9,464 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Alumis by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company's stock valued at $46,000 after buying an additional 979 shares in the last quarter.

Insider Buying and Selling at Alumis

In other Alumis news, Director Srinivas Akkaraju purchased 588,235 shares of the stock in a transaction that occurred on Friday, January 9th. The shares were purchased at an average cost of $17.00 per share, for a total transaction of $9,999,995.00. Following the completion of the transaction, the director owned 1,853,488 shares of the company's stock, valued at $31,509,296. The trade was a 46.49% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Foresite Capital Management Vi acquired 411,764 shares of the company's stock in a transaction that occurred on Thursday, January 8th. The shares were acquired at an average cost of $17.00 per share, with a total value of $6,999,988.00. Following the purchase, the insider owned 5,702,536 shares in the company, valued at $96,943,112. This represents a 7.78% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired 1,823,527 shares of company stock worth $30,999,959 over the last three months. 40.70% of the stock is owned by corporate insiders.

Key Alumis News

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Oppenheimer raised its price target to $55 and kept an "outperform" rating, signaling strong upside from current levels and giving investors a bullish institutional vote of confidence. Oppenheimer raises PT to $55 (Benzinga)
• Positive Sentiment: Morgan Stanley (coverage noted on TipRanks) maintained a Buy rating with a $38 target, citing strong Phase 3 data for Envu and an attractive risk/reward ahead of a planned 2026 FDA submission — a near‑term clinical/regulatory catalyst. Morgan Stanley maintains Buy (TipRanks)
• Positive Sentiment: Chardan Capital reaffirmed a "buy" rating with a $38 target, reinforcing analyst conviction around the clinical story and longer‑term upside. Chardan reaffirms Buy (Benzinga)
• Neutral Sentiment: HC Wainwright trimmed its target from $40 to $25 but left a "buy" rating intact — a mixed signal (reduced upside but continued positive view). HC Wainwright lowers PT to $25 (Benzinga)
• Negative Sentiment: Intraday selling is being attributed to investors locking in gains after roughly a 239% annual rise; technical commentary notes the stock tested/broke short‑term support levels, amplifying the drop. Why Is Alumis Stock Falling Monday? (Benzinga)
• Negative Sentiment: Fundamental pressures remain — recent quarter missed revenue and EPS expectations and the company shows deeply negative margins and ROE — which can make pullbacks sharper and raise the bar for sustained rallies. (Background: Q1 results and metrics)

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.